Jean-Jacques Fournié received his M.S. and Ph.D. degree in microbial biochemistry from the University of Toulouse, Toulouse, France, in 1983 and 1986 respectively. From 1988 to 1989, he was a Postdoctoral Fellow at CIRC (currently Garvan Institute), Sydney University Australia. In 1986, he joined the National Scientific Research Center (CNRS), in Toulouse, France, to study biologically active natural substances, with focus on those activating human cell immunity. In 1990, he settled a cell immunology group focused on non-peptide antigens and he discovered phosphoantigens stimulating human γδ T cells in 1993, and moved this group at the National Institute of Health and Medical Research (INSERM) for pharmacological development of phosphoantigens with therapeutic applications for cancer. In 1999, he co-founded the corporate company Innate Pharma, producing new anticancer treatments. Since 2011, he is currently heading the Cancer Research Center of Toulouse (CRCT), France. His fields of scientific expertise are biochemistry, pharmacology, immunology and cancer. The aim of his team is based on the immune-targeting of hematopoietic diseases.